[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-decompensated-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-decompensated-heart-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,40,78,101,129,151,179,202,224,252,271,301,321,342,371,396,421,446,478,500,535,565],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100642643","therapy-adjustment-and-individualized-response-with-biomarker-observation-in-real-world-heart-failure-100642643",false,"NCT07647848","Therapy Adjustment and IndividuaLized Response With Biomarker Observation in ReaL-world Heart Failure","Therapy Adjustment and IndividuaLized Response With Biomarker Observation in ReaL-world Heart Failure (TAILOR-HF)","TAILOR-HF","Inclusion Criteria:\n\n1. Provide written and dated informed consent for participation prior to trial admission,\n2. Age ≥18 years, female or male\n3. A clinical diagnosis of new onset or worsening of heart failure with a left-ventricular ejection fraction of \\\u003C50%\n4. On treatment with oral or i.v. furosemide ≥40 mg\u002Fday or equivalent (bumetanide 1mg, torasemide 10mg)\n5. Receiving \\\u003C50% of the target doses of at least one of the guidelines recommended pharmacological therapies (clear intolerance not considered)\n6. Anticipated or planned uptitration\n\nExclusion Criteria:\n\n1. Scheduled or on renal replacement therapy,\n2. Clearly documented intolerance to two or more of the following groups of drugs: BB, ARNI, SGLT2i or MRAs.\n3. Diagnosis of peripartum cardiomyopathy, chemotherapy induced cardiomyopathy, current viral myocarditis, right heart failure in absence of left-sided structural disease, pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy including amyloidosis.\n4. The presence of a mechanical assist device,\n5. Scheduled for mechanical assist device or heart transplant,\n6. Current angina pectoris ≥class III,\n7. Requiring valvular surgery or revascularization in the upcoming 3 months or Coronary Artery Bypass Grafting (CABG) within the past 3 months,\n8. Anticipated need for surgery or any other cardiovascular intervention, except implantable cardioverter defibrillator and\u002For cardiac resynchronization therapy, within 4 weeks,\n9. Other non-cardiac conditions with limited life expectancy (≤ duration of the trial\u002F 1 year),\n10. Participation in another clinical trial apart from non-interventional studies.\n11. Patients with an unscheduled hospital visit or admission for reasons that are not primarily related to worsening of heart failure. Therefore, patients with concomitant pulmonary disease, even if severe, valvular disease, acute coronary syndrome or stroke, may be included when the primary diagnosis for admission to hospital or outpatient clinic visit has been heart failure, rather than the concomitant condition.\n12. Women who are pregnant, breastfeeding or those considering becoming pregnant\n13. Subjects unable to provide informed consent.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of TAILOR-HF is to integrate clinical data, laboratory parameters, treatment patterns, and circulating biomarkers to identify factors that predict individual response to pharmacological treatment in patients with heart failure.\n\nTAILOR-HF is an observational study with protocol-mandated assessments scheduled at baseline and at 1, 3, and 6 months after enrolment. Additional follow-up data will be collected through telephone visits every 6 months until the last participant has completed the protocol-mandated 6-month visit.",[26,27],"Chronic Heart Failure","Acute Decompensated Heart Failure","NOT_YET_RECRUITING","2026-06-09",{"date":31,"type":32},"2026-06-15","ACTUAL",{"date":34,"type":21},"2026-09-01",{"date":36,"type":21},"2028-09-01",{"name":38,"class":39},"Maastricht University Medical Center","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100643069","beat-shock-registry-100643069","NCT07643610","BEAT-SHOCK Registry","BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry","BEAT-SHOCK","* Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay\n* Age ≥18 years\n* Provision of written ICF\n* Clinical diagnosis of cardiogenic shock.\n* impaired organ perfusion due to primary cardiac dysfunction,\n* persistent systolic blood pressure (SBP) \\\u003C90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and\n* evidence of systemic hypoperfusion with arterial lactate ≥2 mmol\u002FL or venous lactate ≥3 mmol\u002Fl and ≥1 of the following:\n* Cold or clammy extremities\n* Altered mental status\n* Reduced urine output\n* Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)\n* Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol\u002FL or venous lactate ≥3 mmol\u002Fl) and cardiac dysfunction are present and alternative causes are excluded\n\nExclusion criteria:\n\n* Age \\\u003C18 years\n* Refusal to provide informed consent by the patient or their legally authorized representative",{"count":49,"type":21},8000,"5 Years","This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.",[53,54,55,27,56,57,58],"Cardiogenic Shock","Myocardial Infarction (MI)","Fulminant Myocarditis","Severe Valvular Disease","Post-cardiotomy","Perioperative Cardiogenic Shock",[60,61,62,63,64,65,66],"cardiogenic shock","Myocardial infarction (MI)","Fulminant myocarditis","Acute decompensated heart failure","Severe valvular disease","Post-cardiotomy or perioperative cardiogenic shock","wide range of cardiogenic shock etiologies","RECRUITING","2026-06-08",{"date":70,"type":32},"2026-06-11",{"date":72,"type":32},"2025-10-01",{"date":74,"type":21},"2035-10-01",{"name":76,"class":39},"University Hospital, Basel, Switzerland",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":77},"100636997","a-study-of-acute-decompensated-heart-failure-100636997","NCT07572955","A Study Of Acute Decompensated Heart Failure","HF-FOCUS: Serial Lung Ultrasound And Peripheral Venous Pressure Monitoring To Enhance The Care Of Hospitalized Patients With Acute Decompensated Heart Failure","Inclusion Criteria:\n\n* Subjects ≥18 years of age\n* Admitted to St. Mary's Hospital Cardiology Progressive Care Unit (Cardiology 1-5 teams)\n* Admission diagnosis of either:\n\n  1. Acute systolic heart failure\n  2. Acute on chronic systolic heart failure\n  3. Acute diastolic heart failure\n  4. Acute on chronic diastolic heart failure\n  5. Acute right heart failure\n  6. Acute on chronic right heart failure\n  7. Failure heart biventricular\n* Able to provide informed consent and willing to undergo daily lung ultrasound examinations during their hospitalization.\n\nExclusion Criteria:\n\n* Subjects \\\u003C18 years of age\n* Unable to provide informed consent.\n* Unwilling to undergo daily lung ultrasound examinations.",{"count":86,"type":21},500,"INTERVENTIONAL",[89],"NA","The purpose of this study is to examine shorter hospitalization length as well as a reduced rates of recurrent heart failure hospitalization compared to current standard of care in Acute Decompensated Heart Failure. A 1-day reduction in hospital length of stay in unblinded subjects receiving daily HF-FOCUS examinations compared to a blinded standard of care arm.",[27],"2026-05-01",{"date":94,"type":32},"2026-05-07",{"date":96,"type":21},"2026-06",{"date":98,"type":21},"2028-06",{"name":100,"class":39},"Mayo Clinic",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":87,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":128},"100594350","phase-3-early-discharge-with-subcutaneous-furosemide-versus-standard-care-in-acute-heart-failure-100594350","NCT07018297","Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure","Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure: A Cluster-Randomized Crossover Non-Inferiority Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Within 48 hours of inpatient stay OR ED presentation for HF with plans for admission OR observation stay\u002Fshort-stay hospitalization for HF\n* Expected to require at least 24 additional hours of IV diuretics\n* Adequate home environment for self-care\n* Patient or caregiver capable of operating subcutaneous delivery device\n\nExclusion Criteria:\n\n* Cognitive impairment preventing informed consent\n* Geographic barriers to follow-up\n* Pregnancy or breastfeeding\n* IV furosemide requirement \\>250mg\u002Fday\n* eGFR \\\u003C20 mL\u002Fmin\u002F1.73m2\n* Type 1 myocardial infarction during index admission\n* End-stage HF with receipt or consideration of heart transplant or LVAD or requiring inotropic or mechanical circulatory support\n* Potassium \\\u003C3.0 or \\>6.0 mmol\u002FL or sodium \\\u003C125 mmol\u002FL","100 Years",{"count":110,"type":21},250,[112],"PHASE3","This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation\u002Fshort-stay hospitalization comparing early discharge using subcutaneous furosemide to standard inpatient care. Individual practice groups will serve as \"clusters\" and the unit of randomization. Each participating cluster will implement either the early discharge strategy using the intervention or standard care for initial two-month blocks, followed by a crossover to the alternate strategy. The primary outcome is days alive and out of hospital at 30 days.",[115,27],"Heart Failure",[117,118,119,120],"Subcutaneous Furosemide","Length of Stay (LOS)","Hospitalization","Resource Allocation",{"date":122,"type":32},"2026-05-04",{"date":124,"type":21},"2026-08",{"date":36,"type":21},{"name":127,"class":39},"University of Texas Southwestern Medical Center",2,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":87,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":77},"100537046","reprieve-system-pilot-study-100537046","NCT06272734","Reprieve System Pilot Study","Reprieve System for the Treatment of Subjects With Acute Decompensated Heart Failure Pilot Study","Inclusion Criteria:\n\n1. Hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom (dyspnea, orthopnea, or edema\u002Fswelling) AND 1 sign (peripheral edema, ascites, jugular venous distension, pulmonary vascular congestion on chest radiography)\n2. ≥10 lb. (4.5 kg) above dry weight either by historical weights or as estimated by health care provider.\n3. Patients ≥ 18 years of age able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Inability to place Foley catheter or IV catheter or other urologic issues that would predispose the patient to a high rate of urogenital trauma or infection with catheter placement.\n2. Hemodynamic instability as defined by any of the following: systolic blood pressure \\\u003C90 mmHg, use of vasopressors, use of IV inotropes to treat hypotension (systolic blood pressure \\\u003C90 mm Hg) or suspected\u002Fconfirmed low cardiac output\u002Fshock, mechanical circulatory support, uncontrolled arrhythmias, active severe bleeding, or confirmed or suspected cardiogenic shock. Note: In the absence of the above conditions, use of inotropes to augment diuresis is permitted.\n3. Dyspnea due primarily to non-cardiac causes (e.g., severe chronic obstructive pulmonary disease or pneumonia).\n4. Acute infection with evidence of systemic involvement (e.g., clinically suspected infection with fever or elevated serum white blood cell count).\n5. Estimated glomerular filtration rate (eGFR) \\\u003C 20 ml\u002Fmin\u002F1.73m2 calculated using the MDRD equation or current use of renal replacement therapy (RRT).\n6. Significant left ventricular outflow obstruction, uncorrected complex congenital heart disease, known severe stenotic valvular disease, infiltrative or constrictive cardiomyopathy, acute myocarditis, type 1 acute myocardial infarction requiring treatment (within previous week), or any other pathology that, in the opinion of the investigator, would make aggressive diuresis poorly tolerated.\n7. Inability to follow instructions or comply with follow-up procedures.\n8. Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.\n9. Severe baseline electrolyte abnormalities (e.g., serum potassium \\\u003C3.0 mEq\u002FL or magnesium \\\u003C1.3 mEq\u002FL). Note: These are based on baseline\u002Fscreening labs. Subjects whose electrolyte levels are repleted cannot be reassessed for inclusion in the trial.\n10. Serum sodium \\\u003C135 mmol\u002FL or history of severe hyponatremia\n11. Poorly controlled diabetes\n12. Enrollment in another interventional trial during the index hospitalization\n13. Life expectancy less than 3 months\n14. Women who are pregnant or intend to become pregnant.",{"count":137,"type":21},50,[89],"The objective of the study is to evaluate the use of the Reprieve System to decongest subjects with acute decompensated heart failure.",[27],"2026-02-03",{"date":143,"type":32},"2026-02-05",{"date":145,"type":32},"2024-01-23",{"date":147,"type":21},"2026-12-31",{"name":149,"class":150},"Reprieve Cardiovascular, Inc","INDUSTRY",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":87,"phases":160,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":77},"100621547","phase-2-add-on-diuretics-in-acute-decompensated-heart-failure-100621547","NCT07372040","Add-on Diuretics in Acute Decompensated Heart Failure","Clinical Study Comparing Empagliflozin, Acetazolamide, and Metolazone as Add-on Therapies to Loop Diuretics in Acute Decompensated Heart Failure","Inclusion Criteria:\n\n1. Male or female patients older than 18 years.\n2. Hospital admission with clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography).\n\nExclusion Criteria:\n\n1. Type 1 diabetes.\n2. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin per 1.73 m² or end-stage kidney failure with the need for chronic dialysis treatment.\n3. A systolic blood pressure of less than 90 mmHg.\n4. Cardiogenic shock.\n5. Receipt of acetazolamide maintenance therapy.\n6. Receipt of an SGLT2 inhibitor, thiazide, or thiazide-like diuretic in the 48 hrs before randomization.\n7. Any cause of heart failure leading to decompensation that will need urgent management (eg, acute coronary syndrome, unstable arrhythmias, acute pulmonary embolism).\n8. Pregnant or breastfeeding women.\n9. Moderate to severe anemia.",{"count":159,"type":21},66,[161],"PHASE2","The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.",[27],[165,166,167,168,169],"Empagliflozin","Acetazolamide","Metolazone","Acute heart failure","Add-on therapies to Loop diuretics","2026-02-02",{"date":172,"type":32},"2026-02-04",{"date":174,"type":21},"2026-02-01",{"date":176,"type":21},"2027-02-01",{"name":178,"class":39},"Tanta University",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":187,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":87,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},"100585142","phase-3-fluid-management-of-acute-decompensated-heart-failure-subjects-treated-with-reprieve-system-fastr-ii-ide-g210258-100585142","NCT06898515","Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)","Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II)","FASTR-II","Inclusion Criteria:\n\n1. Diagnosis of HF with expected hospitalization \\>24 hours, with \\>1 new or worsening symptom and \\>2 physical examination, laboratory, or invasive findings of HF, and receiving or with plans to receive a HF-specific treatment\n2. ≥10 lb. (4.5 kg) above dry weight as estimated by health care provider.\n3. Current outpatient prescription for daily loop diuretic.\n4. Participants ≥ 22 years of age able to provide informed consent and comply with study procedures.\n5. Elevated risk of diuretic resistance, as indicated by at least one of the following: Baseline hypochloremia OR Urine output \\\u003C1L in the 6 hours following IV loop diuretic \\>=40 mg furosemide equivalent OR Spot urine sodium \\\u003C100 mmol\u002FL 1-2 hours after IV loop diuretic \\>= 40 mg furosemide equivalent\n\nExclusion Criteria:\n\n1. Urologic issues that would predispose the participant to a high rate of urogenital trauma or infection with catheter placement or known inability to place a Foley catheter.\n2. Hemodynamic instability as defined by any of the following: sustained systolic blood pressure \\\u003C90 mmHg for \\>15 minutes within the past 48 hours, use of IV vasopressors or inotropes within past 48 hours, and\u002For current or previous mechanical circulatory support within the last week.\n3. Uncontrolled arrhythmias defined as sustained HR \\>130 beats\u002Fmin for \\>10 minutes within the past 48 hours.\n4. Severe lung disease with chronic home oxygen requirement \\>2L\u002Fmin.\n5. Acute infection with evidence of systemic involvement (e.g., clinically suspected infection with fever or elevated serum white blood cell count).\n6. Estimated glomerular filtration rate (eGFR) \\\u003C25 ml\u002Fmin\u002F1.73m2 (calculated with either MDRD or CKD-EPI) or current use of renal replacement therapy (RRT).\n7. Significant left ventricular outflow obstruction, severe uncorrected complex congenital heart disease, known severe stenotic valvular disease, severe infiltrative or constrictive cardiomyopathy or other diagnosis that would make aggressive decongestion unsafe.\n8. Current or recent (\\\u003C 30 days) type I myocardial infarction (e.g., acute coronary syndrome such as NSTEMI or STEMI from plaque rupture), coronary artery bypass surgery, or stroke. An isolated troponin elevation (e.g., from volume overload or demand ischemia) is not a reason for exclusion.\n9. Severe electrolyte abnormalities (e.g., serum potassium \\\u003C3.0 mEq\u002FL, magnesium \\\u003C1.3 mEq\u002FL or sodium \\\u003C125 mEq\u002FL). Note: These are based on baseline\u002Fscreening labs. Participants whose electrolyte levels are repleted cannot be reassessed for inclusion in the trial.\n10. Other concomitant disease or condition the investigator believes will make it difficult to follow instructions or comply with study procedures and\u002For follow-up visits, including expected prolonged hospitalization for reasons other than decongestive therapy\n11. Currently enrolled in an interventional trial (observational studies are permitted).\n12. Life expectancy less than 6 months.\n13. Women who are pregnant or breastfeeding.","22 Years",{"count":189,"type":21},400,[112],"The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.",[27],"2025-11-24",{"date":195,"type":32},"2025-11-26",{"date":197,"type":32},"2025-07-14",{"date":199,"type":21},"2027-12",{"name":149,"class":150},53,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":87,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":77},"100608248","comparative-efficacy-and-safety-of-acetazolamide-versus-metolazone-as-an-adjunct-to-standard-therapy-in-patients-with-acute-decompensated-heart-failure-100608248","NCT07199088","Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Diagnosed with Acute Decompensated Heart Failure (ADHF), with either preserved or reduced ejection fraction (EF).\n* At least one clinical sign of volume overload, such as:\n* Pleural effusion (confirmed by chest X-ray or ultrasound).\n* Oedema or ascites (verified by abdominal ultrasonography).\n* Plasma NT-proBNP level \\> 1000 pg\u002FmL or BNP level \\> 250 ng\u002FmL at screening.\n* Receiving at least 40 mg of furosemide as oral maintenance therapy for at least one month prior to the study initiation.\n\nExclusion Criteria:\n\n* Previous use of acetazolamide or metolazone prior to the study period.\n* Known hypersensitivity or allergies to the study drugs (acetazolamide or metolazone) or their components.\n* Patients with electrolyte disturbances, especially hypokalemia.\n* End-stage renal disease requiring dialysis or GFR \\\u003C 20 mL\u002Fmin\u002F1.73 m².\n* Pregnant or breastfeeding women.\n* Severe hypotension (systolic blood pressure \\\u003C 90 mmHg) or other significant comorbidities like congenital cardiac illness requiring surgery.\n* Patients requiring renal replacement therapy during the hospitalization.\n* History of significant electrolyte imbalances or acid-base disturbances.",{"count":209,"type":21},320,[89],"This clinical trial aims to compare the efficacy and safety of acetazolamide versus metolazone as adjunctive treatments to standard therapy in patients with acute decompensated heart failure (ADHF). ADHF is a life-threatening condition, and current treatments often involve loop diuretics to alleviate volume overload. This study will assess the added benefit of acetazolamide and metolazone in improving decongestion, reducing hospital stays, and preventing complications such as renal dysfunction or electrolyte imbalances. Participants will be randomized to receive either acetazolamide or metolazone in addition to standard diuretic therapy. The trial will evaluate primary outcomes including successful decongestion, in-hospital mortality, and length of hospital stay, with secondary outcomes focusing on renal function, electrolyte disturbances, and overall safety. The study is conducted at Bahawal Victoria Hospital, Bahawalpur, and aims to provide valuable insights into the management of ADHF, especially in the Pakistani population.",[27,213,214],"Heart Failure, Diastolic","Heart Failure, Systolic","2025-09-29",{"date":217,"type":32},"2025-10-03",{"date":219,"type":21},"2025-10-11",{"date":221,"type":21},"2026-10-30",{"name":223,"class":39},"University of Health Sciences Lahore",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":87,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":77},"100528531","each-adhf-early-comprehensive-rehabilitation-in-patients-with-adhf-100528531","NCT06161987","EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF","Efficacy and Safety of Early Comprehensive Rehabilitation in Patients With ADHF, A Multicenter, Randomized, Controlled Trial.","EACH-ADHF","Inclusion Criteria:\n\n1. Age between 18-80\n2. At least one symptom of heart failure upon admission:\n\n   Dyspnea at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea or exertional fatigue.\n3. At least two of the signs of heart failure (HF):\n\n   Distended jugular veins, enlarged cardiac silhouette, apex beat displacement, third heart sound, or increased jugular venous pressure\u002Fcentral venous pressure\u002Fpulmonary capillary wedge pressure.\n\n   Pulmonary edema or pulmonary congestion (rales or chest X-ray\u002FCT evidence of pulmonary congestion).\n\n   Peripheral edema. Elevated B-type natriuretic peptide (\\>100 pg\u002Fml) or elevated NT-proBNP (\\>300 pg\u002Fml).\n4. Able to independently perform basic activities of daily living before admission.\n5. Able to complete the baseline assessment and initiate the specified treatment.\n6. Able to walk 4 meters at the time of enrollment (assistive devices may be used).\n7. Agree to participate in this study, sign a written informed consent form, and is willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Acute heart failure caused by acute myocardial infarction.\n2. Severe aortic valve stenosis.\n3. Hemodynamic instability caused by poorly controlled arrhythmias.\n4. Severe heart failure and high-degree atrioventricular block, and inadequate heart rate response to pacing during exercise.\n5. Isolated pulmonary hypertension.\n6. Poorly controlled symptomatic orthostatic hypotension.\n7. Hypertrophic obstructive cardiomyopathy.\n8. Stage 5 chronic kidney failure, defined as glomerular filtration rate \\\u003C15 ml\u002F(min·1.73m²) or requiring dialysis.\n9. Undergoing screening tests with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than or equal to 5 times the upper limit of the normal range defined by the center.\n10. Awaiting a heart transplant or ventricular assist device implantation within six months, or having received a heart transplant.\n11. A history of chronic lung disease except for COPD, previous lung surgery, or diseases affecting lung function, such as scoliosis.\n12. Late-stage diseases other than heart failure.\n13. Any medical history that could potentially affect protocol compliance, such as severe mental disorders, severe cognitive impairment, substance abuse, or addiction.\n14. Severe language, psychological, or physical disabilities that prevent their participation in the program.\n15. Pregnant or lactating women, or those of childbearing potential who are unwilling or unable to use effective contraceptive measures.\n16. Involved in other interventional clinical trials.\n17. Patients deemed unfit for participation in this study by the researchers.","80 Years",{"count":234,"type":21},140,[89],"EACH-ADHF: Early Comprehensive Rehabilitation in patients with ADHF study is a multi-center, parallel-group, randomized controlled trial designed to evaluate the effects of the early comprehensive rehabilitation including exercise and inspiratory muscle training, over a period of 6 weeks, on the quality of life of patients with ADHF.",[27],[63,239,240,241,242],"Early comprehensive rehabilitation","Inspiratory muscle training","Exercise training","KCCQ","2025-08-13",{"date":245,"type":32},"2025-08-17",{"date":247,"type":32},"2023-12-01",{"date":249,"type":21},"2027-06-30",{"name":251,"class":39},"Guangdong Provincial People's Hospital",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":259,"conditions":260,"keywords":261,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":77},"100114971","circulating-markers-that-underlie-the-transition-from-compensated-hypertrophy-to-heart-failure-100114971","NCT00762008","Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure","Inclusion Criteria:\n\n* Individuals aged \\>18yrs\n* stable or decompensated heart failure, irrespective of LVEF\n* decompensated heart failure clinical symptoms such as dyspnea, rales, edema, elevated jugular venous pressure, or ascites\n* Imaging evidence of heart failure (cardiomegaly, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures)\n* Healthy individuals with no prior history of heart attack or heart failure will be recruited to use as controls.\n\nExclusion Criteria:\n\n* Subjects who are unable to give informed consent\n* Subjects who had undergone cardiac or non-cardiac surgery in the 3 months before enrollment\n* Pregnant subjects are not excluded",{"count":86,"type":21},"The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.",[27,115],[262],"biomarkers","2025-08-10",{"date":265,"type":32},"2025-08-12",{"date":267,"type":4},"2005-12",{"date":199,"type":21},{"name":270,"class":39},"UConn Health",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":87,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":300},"100358776","using-an-intervention-adapted-to-the-health-literacy-level-to-improve-adherence-to-medical-recommendations-100358776","NCT03951467","Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations","Impact of a Strategy Dedicated to Low Health Literacy Level Patients to Improve Their Understanding and Ownership of the Discharge Prescription in Cardio-vascular Diseases","ILIADE","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Hospitalization for at least a 2nd acute attack (systolic or diastolic)\n* Patient living at home before hospitalization for decompensation\n* Affiliated with a health insurance plan\n\nExclusion Criteria:\n\n* Short-term vital prognosis\n* Bipolar disorders, active psychoses\n* Severe dementia\n* Psychiatric or cognitive comorbidities making inclusion impossible, at the discretion of the investigator.\n* Pregnant, parturient or breastfeeding women\n* Persons deprived of liberty by a judicial or administrative decision\n* Persons admitted to a health or social establishment for purposes other than research\n* Adults subject to a legal protection measure (guardianship, curatorship)\n* Subject participating in another interventional research including an exclusion period still ongoing at inclusion\n* Score S-TOFHLA (\\>22)\n* Withdrawal of consent",{"count":280,"type":21},300,[89],"Health literacy is the ability to access, understand, evaluate and apply information in order to communicate with health professionals and understand health instructions but also, promote, maintain and improve health throughout life. Health literacy is known as a health determinant. Level of Health Literacy is low or limited within 47% of interrogated people in Europe, resulting in an inability to understand and\u002For use written texts and digital concepts about one's health.\n\nThere is a demonstrated link between low HL and low therapeutic adherence, an increase in the number of re-admissions, and more generally poor health or survival that is even more limited. An association between low LS and higher health care costs has also been reported in the USA and Switzerland. WHO highlight the central role of Health Literacyin health inequalities, regardless of the region of the world.\n\nThe investigator chose to conduct this study in patients hospitalized for an acute cardiovascular event: acute myocardial infarction or acute decompensated heart failure , as these patients have cumulative risk factors for misuse and medication errors. They are hospitalized in emergency, for shorter and shorter periods and are discharged with complex drug treatments. The data show that the return home after acute hospitalization for these conditions is a particularly high-risk period for medication errors and misuse, especially with low level of Health Literacy. The proportion of patients with preventable adverse events in the weeks following their return home ranges from 23% to 30% and nearly 60% are re-hospitalized within 6 months.\n\nThe hypothesis of the study is that in patients hospitalized for cute myocardial infarctionor acute decompensated heart failurewith low Health Literacy levels, information on discharge treatment using appropriate tools and techniques will reduce the risk of patient-related medication errors or misuse within 30 days of discharge.\n\nThe purpose of this study is to develop an educational intervention model adapted to low Health Literacy levels and routinely feasible, even in case of short stays, in complementarity with traditional therapeutic education programmes that require higher investments and are therefore not accessible to all patients. This innovative approach could then be applied to a large number of chronic diseases.",[27,284],"Acute Myocardial Infarction",[286,287,288,289,290,291],"Literacy","Cardiovascular Diseases","Interventional study","Randomized Controlled Trial","Tertiary prevention","Health promotion","2025-07-09",{"date":197,"type":32},{"date":295,"type":32},"2025-06-26",{"date":297,"type":21},"2027-12-26",{"name":299,"class":39},"Hospices Civils de Lyon",4,{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":87,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":300},"100497635","safety-and-performance-evaluation-of-the-nephronyx-system-for-the-treatment-of-patients-with-adhf-100497635","NCT05759806","Safety and Performance Evaluation of the Nephronyx System for the Treatment of Patients With ADHF","Inclusion Criteria:\n\n* Patient admitted to the hospital with a primary diagnosis of ADHF\n* Patient has signs of volume overload as evidence by a score of ≥ 4 on the EVEREST score\n* Patient with Left Ventricular Ejection Fraction LVEF \\>15%\n* Patient has compromised response to diuretics\n* NT-proBNP \\>450 pg\u002FmL if aged \\\u003C55 years, \\>900 pg\u002FmL if aged between 55 and 75 years and \\>1800 pg\u002FmL if aged \\>75 years\n\nExclusion Criteria:\n\n* Patient with active DVT or history of DVT\n* Patient has documented or evidence of Renal artery stenosis\n* BMI\\>35 Kg\u002Fm\\^2\n* Patient has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization\n* Patient is in Cardiogenic shock\n* Patient has blood dyscrasia, acute anemia, thrombocytopenia, bleeding diathesis, or coagulopathy\n* Temperature \\> 38°C, or sepsis, or active systemic infection requiring IV anti-microbial treatment\n* Patient has shown liver cirrhosis or has signs of liver damage",{"count":308,"type":21},10,[89],"The objective of this interventional study is to evaluate the safety and functional performance of the Nephronyx System in patients with ADHF, presenting clinical signs of volume overload and compromised response to diuretics.",[27],"2025-05-21",{"date":314,"type":32},"2025-05-25",{"date":316,"type":32},"2022-12-19",{"date":318,"type":21},"2026-07",{"name":320,"class":150},"Nephronyx LTD",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":232,"enrollmentInfo":329,"targetDuration":4,"studyType":87,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":77},"100277965","low-level-tragus-stimulation-in-acute-decompensated-heart-failure-100277965","NCT02898181","Low Level Tragus Stimulation in Acute Decompensated Heart Failure","Low Level Transcutaneous Tragus Stimulation to Reduce Inflammation, Dyspnea and Improve Heart Rate Variability in Acute Decompensated Heart Failure","TREAT-HF","Inclusion Criteria:\n\nPatients admitted with ADHF\n\nExclusion Criteria:\n\n1. Refusal to consent\n2. Complex congenital heart disease (Tetralogy of Fallot patients, single ventricle physiology)\n3. Recurrent vaso-vagal syncopal episodes\n4. Unilateral or bilateral vagotomy\n5. Sick sinus syndrome\n6. 2nd or 3rd degree AV block\n7. bifascicular block or prolonged 1st degree AV block (PR\\>300ms)\n8. Pregnant patients\n9. Prisoners\n10. Advanced renal dysfunction(defined as eGFR \\\u003C 30, stage 4 or 5 chronic kidney disease)\n11. Hepatitis C or HIV\n12. Acute Myocardial infarction",{"count":330,"type":21},100,[89],"Acute Decompensated Heart Failure (ADHF) is a major cause of morbidity and mortality. It is associated with increased systemic inflammation. Previous studies have demonstrated increased levels of cytokines such as C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10) and Tumor Necrosis Factor alpha (TNFα) in patients with heart failure (HF). Increased activity of sympathetic nervous system in ADHF is linked to inflammation. Previous anti-inflammatory drug therapies in HF have demonstrated no significant impact on cardiovascular outcomes. Low-level vagus nerve stimulation (LLVNS) is a non-invasive way to modulate autonomic tone and thereby inflammation. Vagal nerve stimulation is thought to increase the parasympathetic activity and suppress the sympathetic activity. Clinical studies of vagal stimulation in chronic HF have been negative. Recent experimental and clinical data suggest that low level tragus nerve stimulation (LLTNS) may produce the same desired neuromodulator effect compared to LLVNS. It is however unknown if LLTNS in ADHF will directly lead to a reduction in the levels of pro-inflammatory cytokines (CRP, IL-1, IL-6 and TNF-α) and an increase in the level of anti-inflammatory marker IL-10. heart rate variability may also be abnormal in ADHF. The objective of this proposal is to determine the impact of LLTS on inflammatory cytokines, heart failure biomarkers(Pro BNP) and HRV in patients with ADHF.In addition we will study the impact on dyspnea resolution and change in renal function during hospitalization.\n\nPatients will be randomized to either active or sham stimulation (2 hours daily). Serum collected will (post-admission and discharge day) will be used for cytokine measurement. We will also measure daily ECG to assess HRV and patient assessed dyspnea scale.This investigation will likely establish the first evidence of the effects of LLTS on the suppression of inflammation and improvement in dyspnea, natriuretic peptides, renal function and HRV in patients presenting with ADHF.",[27],{"date":335,"type":32},"2025-05-28",{"date":337,"type":4},"2016-09",{"date":339,"type":21},"2026-09",{"name":341,"class":39},"University of Oklahoma",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":87,"phases":352,"briefSummary":353,"conditions":354,"keywords":357,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":369,"locationsCount":77},"100570989","venous-ultrasound-guided-organ-decongestion-in-patients-hospitalized-with-acute-decompensated-heart-failure-100570989","NCT06714409","Venous Ultrasound Guided Organ Decongestion in Patients Hospitalized with Acute Decompensated Heart Failure","A Parallel-group, Single-center, Two-arm Treatment Study to Assess the Safety and Effectiveness of Venous Ultrasound Guided Decongestion in Adult Patients Hospitalized with Acute Decompensated Heart Failure.","VExOUS-ADHF","Inclusion Criteria:\n\n* 18 years of age or above\n* Admitted the ward of Department of Cardiology OUH Ullevål with a clinical diagnosis of ADHFdefined by European Society of Cardiology\n* Pro-BNP \\> 800 ng\u002Fl at first day of admission\n* Capable of giving signed informed consent\n\nExclusion Criteria:\n\n\\- Any medical or psychiatric condition which in the opinion of the investigatorprecludes participation",{"count":351,"type":21},180,[89],"The purpose of this study is to assess the feasibility, safety and effectiveness of VExUS guided organ decongestion compared to standard of care in patients hospitalized with acute decompensated heart failue (ADHF).\n\n180 patients will be randomly assigned to either intervention (VExUS) arm or standard of care (SOC) arm. In the intervention arm, the treatment team will be informed by the study team about the results of the VExUS examination to supplement the clinical decision of proper decongestion treatment, while no information will be provided in the standard of care arm. Study visits are scheduled every second day while hospitalized, end of study is set to day of discharge from the ward. Telephone consultation and review of medical journal scheduled after 6 months to assess exploratory endpoints.\n\nThe overall rationale of the the study is to investigate if venous organ congestion investigated by VExUS score, is a modifiable risk factor in patients hospitalized with ADHF. And secondary to assess if venous organ decongestion guided by VExUS score may safely be implemented in patients hospitalized with ADHF and result in:\n\n* differences in length of hospitalization\n* changes in biomarkers of cardiac strain\n* changes in renal function and markers of renal injury\n* achieved doses of heart failure treatment at discharge\n* in-hospital complications\n\nSafety measures with special attention on symptomatic hypotension, arrhythmias, metabolic alkalosis and electrolyte disturbances will be addressed.",[355,115,356,27],"Cardiorenal Syndrome","Acute Kidney Injury",[358,359,360,361,362],"Cardiorenal syndrome","Acute kidney injury","Heart failure","VExUS","Venous congestion","2024-11-28",{"date":365,"type":32},"2024-12-03",{"date":367,"type":32},"2024-09-16",{"date":72,"type":21},{"name":370,"class":39},"Oslo University Hospital",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":87,"phases":380,"briefSummary":382,"conditions":383,"keywords":384,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":128},"100552593","phase-4-combination-oral-acetazolamide-and-intravenous-furosemide-on-acute-decompensated-heart-failure-outcomes-100552593","NCT06475105","Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes","Effects of Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure","COAF-HF","Inclusion Criteria:\n\n* Agree to be included in the research by signing informed consent\n* Patients with a clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload with a congestion score ≥2 (ADVOR Score) (e.g. edema (score 2 or more), ascites confirmed by physical examination or ultrasonography or pleural effusion confirmed by chest x-ray or echocardiography).\n* Patients on routine oral loop diuretic therapy with a dose of ≥40 mg furosemide for ≥1 month\n* Plasma NT-proBNP levels that increase ≥300 pg\u002FmL or the applicable cut-off according to the age range at the time of examination in the ER.\n\nExclusion Criteria:\n\n* Subjects with acute coronary syndrome\n* History of congenital heart disease requiring surgical correction.\n* Subjects in cardiogenic shock.\n* Estimated glomerular filtration rate \\\u003C20 mL\u002Fmin\u002F1.73m² at the time of examination.\n* Use of renal replacement therapy or ultrafiltration at any time before the study was included.\n* Treatment with acetazolamide within 1 month before randomization.\n* Exposure to nephrotoxic agents (i.e. contrast dye) is anticipated within the next 3 days\n* Subjects who are pregnant or breastfeeding.\n* Subjects with urinary incontinence who are unwilling to use a bladder catheter.",{"count":159,"type":21},[381],"PHASE4","Based on ADVOR trial, the potential of adding acetazolamide in increasing the success of decongestion, the amount of natriuresis and diuresis. However, the use of intravenous acetazolamide may not be possible in Indonesia, where the intravenous formulation is not available. This clinical research study is being conducted in single hospitals in Indonesia. We aim to learn if Oral Acetazolamide in addition to Furosemide intravenous works to treat congestion in Acute Decompensated Heart Failure, besides evaluating the total urinary output, change of NT pro BNP level, and safety profile of oral Acetazolamide.\n\nThe hypothesis of this study is oral acetazolamide works well to achieve successful decongestion.",[27],[385,27,386],"Oral Acetazolamide","Congestion","2024-10-20",{"date":389,"type":32},"2024-10-22",{"date":391,"type":32},"2024-04-20",{"date":393,"type":21},"2024-12-31",{"name":395,"class":39},"Universitas Diponegoro",{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":403,"enrollmentInfo":404,"targetDuration":406,"studyType":23,"phases":4,"briefSummary":407,"conditions":408,"keywords":409,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":77},"100561119","the-association-between-visual-echocardiographic-scoring-system-and-clinical-outcomes-in-patient-with-acute-decompensated-heart-failure-100561119","NCT06586008","The Association Between Visual Echocardiographic Scoring System and Clinical Outcomes in Patient With Acute Decompensated Heart Failure","VISCO-HF","Inclusion Criteria:\n\n* Patient with history of heart failure with reduced ejection fraction (LVEF \\\u003C40%)\n* Age between 18 - 70 years old\n\nExclusion Criteria:\n\n* Patient with pulmonary hypertension\n* Patient with acute de novo heart failure (e.g. due to acute coronary syndrome)\n* Significant valvular heart disease (more than moderate regurgitation or more than mild stenosis)\n* Prior valve replacement\u002Frepair\n* Patient with congenital heart disease\n* Patient with pericardial disease\n* Patient with poor echocardiographic images","70 Years",{"count":405,"type":21},150,"7 Days","This study aims to evaluate the association between visual echocardiographic scoring system (visual mitral and tricuspid = VMT score) with clinical outcome among patients with acute decompensated heart failure. Researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as acute decompensated heart failure. The data consist of demographic data, clinical presentation, laboratory, and echocardiographic result were collected from hospital registry by reviewing medical record and echocardiographic machine database. Then, the data was analyzed by using IBM SPSS Statistics v26.",[27],[410,411,412],"visual echocardiographic system","acute decompensated heart failure","mortality","2024-09-03",{"date":415,"type":32},"2024-09-19",{"date":417,"type":32},"2024-01-01",{"date":419,"type":21},"2024-11-10",{"name":395,"class":39},{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":87,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":77},"100557239","phase-3-acetazolamide-versus-dapagliflozin-in-acute-decompensated-heart-failure-patients-100557239","NCT06535529","Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients","Inclusion Criteria:\n\n* Male or female patients of 18 years of age or older.\n* An elective or emergency hospital admission with clinical diagnosis of decompensated HF with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography).\n* Assessed LVEF by any imaging technique; i.e. echocardiography, catheterization, nuclear scan magnetic resonance imaging within 12 months of inclusion.\n\nExclusion Criteria:\n\n* The receipt of acetazolamide maintenance therapy.\n* Receipt of an SGLT2 inhibitor in the 48 hours before randomization.\n* An estimated glomerular filtration rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73 m2.\n* Use of any non-protocol defined diuretic agent with the exception of mineralocorticoid receptor antagonists during the treatment phase of the study. Thiazides, metolazone, indapamide and amiloride should be stopped upon study inclusion. If patient is taking a combination drug including a thiazide-type diuretic, the thiazide-type diuretic should be stopped.",{"count":428,"type":21},60,[112],"The goal of this clinical trial is to compare the effectiveness of acetazolamide versus dapagliflozin as an add-on in treating acute decompensated heart failure (ADHF) in adult patients with clinical signs of volume overload requiring intravenous loop diuretics. It will also assess the safety of these drugs when added to standard care. The main questions it aims to answer are:\n\n* Does acetazolamide or dapagliflozin lead to a greater reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels?\n* Which drug results in better loop diuretic efficiency, as measured by weight loss per 40 mg of intravenous furosemide or equivalent? We will compare acetazolamide to dapagliflozin, both added to standard intravenous loop diuretic therapy, to see which is more effective in decongesting patients with ADHF.\n\nParticipants will:\n\n* Take either acetazolamide or dapagliflozin orally every day for 3 days\n* Receive intravenous loop diuretics as part of standard care\n* Undergo regular assessments of heart failure symptoms, weight, and laboratory tests\n* Be followed up until hospital discharge and for 30 days after starting the study",[27],[433,434,166,435,436],"Acute Heart failure","ADHF","SGLT2 inhibitors","SGLT2i","2024-08-01",{"date":439,"type":32},"2024-08-05",{"date":441,"type":21},"2024-08-24",{"date":443,"type":21},"2025-09-01",{"name":445,"class":39},"Helwan University",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":87,"phases":455,"briefSummary":456,"conditions":457,"keywords":460,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":77},"100547959","phase-4-efficacy-and-safety-of-combination-diuretic-therapy-in-patients-with-acute-decompensated-heart-failure-and-volume-overload-100547959","NCT06414759","Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload","Inclusion Criteria:\n\n* Male or female patients with ages ≥ 18 years old, and less than 65 years old.\n* For both elective and emergency hospital admissions, patients with a clinical diagnosis of ADHF must exhibit at least one clinical sign indicative of volume overload. These signs may include edema (score 2 or higher), ascites confirmed through echography, or pleural effusion confirmed by chest X-ray or echography or rales on auscultation, or jugular venous pressure greater than10 mm Hg.\n\nExclusion Criteria:\n\n* Patient diagnosed with acute kidney injury upon hospital admission based on the presence of any of the following criteria: an increase in SCr by at least 0.3 mg\u002FdL within 48 hours, an increase in SCr to at least 2 times the baseline value, known or presumed to have occurred within the prior 7 days, and a urine volume less than 0.5 ml\u002Fkg\u002Fhour for a duration of 6 hours.\n* Patients with acute pulmonary edema caused by increased afterload and fluid redistribution to the lungs in the absence or with minimal fluid accumulation.\n* Anticipated exposure to nephrotoxic agents (such as contrast dye) during hospitalization.\n* Patients who exhibit anuria or are undergoing renal replacement therapy or ultrafiltration.\n* Patients with eGFR less than 30 mL\u002Fmin\u002F1.73m² at the time of screening.\n* Expected use of intravenous inotropes, vasopressors, or nitroprusside during the study.\n* Prior cardiac transplantation and\u002For utilization of a ventricular assist device.\n* Blood pressure below 90 mmHg or mean arterial pressure below 65 mmHg at the time of recruitment.\n* Patients who are pregnant or breastfeeding.\n* Administration of acetazolamide or metolazone within the one-month period preceding randomization.\n* The usage of any diuretic agent during the treatment phase is not specified in the study protocol, except for mineralocorticoid receptor antagonists.","65 Years",{"count":454,"type":21},110,[381],"This study aims to compare two medications, acetazolamide and metolazone, along with loop diuretics, to see which one works better and is safer for patients with ADHF who have volume overload. By comparing these medications, we hope to learn which one can help these patients the most. This will help doctors choose the best treatment for patients with ADHF and volume overload.",[27,458,459],"Volume Overload","Edema",[434,27,461,462,463,459,464,465,167,166,466,467,468],"AHF","Acute Heart Failure","Volume overload","Loop diuretics","Fusrosemide","Carbonic anhydrase inhibitor","Thiazide like diuretics","Thiazide diuretics","2024-07-23",{"date":471,"type":32},"2024-07-24",{"date":473,"type":32},"2024-07-01",{"date":475,"type":21},"2025-03-30",{"name":477,"class":39},"Cairo University",{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":486,"targetDuration":406,"studyType":23,"phases":4,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":498,"locationsCount":77},"100551363","adherence-to-medication-in-patients-with-acute-decompensated-heart-failure-100551363","NCT06459115","Adherence to Medication in Patients With Acute Decompensated Heart Failure","Adherence to Medication in Patients With Acute Decompensated Heart Failure: a Cross-sectional Study at the Emergency Department (ADHF-ED= Adherence to Medication in Patients With Acute Decompensated Heart Failure at the Emergency Department)","ADHF-ED","Inclusion Criteria:\n\n* age ≥18 years of age\n* known chronic heart failure irrespective of ejection fraction (heart failure with reduced, mildly reduced, or preserved ejection fraction)\n* requirement of intravenous diuretics (outpatient or stationary treatment)\n* stable heart failure medication \\>2 weeks\n* ≥1 sign of volume overload (peripheral edema, jugular venous distension, pulmonary rales, ascites, or demonstration of pulmonary venous congestion on chest X-ray)\n* elevated natriuretic peptides (N-terminal pro brain natriuretic peptide= nt-pro-BNP ≥125 pg\u002Fml)\n\nExclusion Criteria:\n\n\\- Not able to give written informed consent",{"count":330,"type":21},"Every day, patients present to emergency department due to acute heart failure. There are many causes for decompensation. One possible cause is a lack of adherence to heart failure medication (prognosis-improving medications and diuretics). The aim of this study is to directly measure adherence in patients with acute heart failure (gold standard of adherence measurement using liquid chromatography coupled to high-resolution mass spectrometry= LC-HRMS\u002FMS) at the emergency department. Questionnaires are used to investigate possible factors influencing adherence.",[27],[27,490,491],"Adherence","Emergency department","2024-06-17",{"date":494,"type":32},"2024-06-20",{"date":496,"type":32},"2023-02-01",{"date":393,"type":21},{"name":499,"class":39},"Universität des Saarlandes",{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":17,"minAge":507,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":87,"phases":510,"briefSummary":511,"conditions":512,"keywords":517,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":509},"100529503","feasibility-study-to-support-cardiorenal-function-in-acute-decompensated-heart-failure-with-diuretic-resistance-100529503","NCT06174623","Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance","Early Feasibility Study to Mechanically Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance","Inclusion Criteria:\n\n1. Admitted to the hospital with a primary diagnosis of ADHF\n2. Clinical signs and\u002For symptoms of congestion defined as at least one of the following: dyspnea at rest or with minimal exertion, orthopnea, lower extremity edema (≥2+), elevated jugular venous pressure, pulmonary rales, pulmonary vascular congestion on chest x-ray, pleural effusion or ascites\n3. Projected need by the treating clinician for continued treatment with IV diuretic agents for more than 48 hours with the goal of significant fluid removal (more than 1L net fluid loss\u002F24h)\n4. Appropriate intravenous loop diuretic therapy at the time of enrollment, defined as at least the higher of:\n\n   1. Furosemide 40mg IV bid or equivalent\n   2. IV furosemide or equivalent IV loop diuretic equivalent to ≥2x the total oral daily loop diuretic dose at home in 2 divided doses\n5. Diuretic resistance defined as at least ONE of the following:\n\n   1. Urine output of less than 1.5L over 12h following the last diuretic dose, OR\n   2. Net fluid loss of less than 1L over the last 24 hours, OR\n   3. Spot urinary sodium concentration of less than 70 mmol\u002FL 2h following the last diuretic dose or cumulative 6-hour natriuresis of less than 100 mmol following the last diuretic dose, OR\n   4. Clinically unsatisfactory resolution of congestion\n6. Age ≥ 21 years old\n7. Signed informed consent\n\nExclusion Criteria:\n\n1. ADHF related to acute secondary disease (i.e., infection or acute coronary syndrome)\n2. Treatment with high dose inotropes (milrinone ≥0.375 mcg\u002Fkg\u002Fmin, dobutamine ≥5mcg\u002Fkg\u002Fmin or dopamine ≥5mcg\u002Fkg\u002Fmin) and\u002For treatment with vasopressors to maintain a systolic arterial blood pressure ≥90 mmHg or mean arterial blood pressure ≥60 mmHg\n3. Current or previous support with a durable left ventricular assist device (LVAD) at any time or use of an extracorporeal membrane oxygenation (ECMO), percutaneous ventricular assist devices, intra-aortic balloon pump or patient on home inotropes currently or within the last 30 days\n4. Recent myocardial infarction, percutaneous coronary intervention or surgical revascularization (within the last 30 days) or awaiting planned coronary intervention or surgery\n5. Fixed pulmonary vascular resistance of more than 5 Wood units, estimated PASP of more than 80 mmHg as measured on echocardiogram or echocardiographic evidence of primarily right heart failure\n6. Prior heart transplant, heart failure due to rejection of a previous heart transplant, or planned heart transplantation\n7. Reanimated cardiac arrest in the last 30 days\n8. Suspected or known amyloid disease or other restrictive cardiomyopathy\n9. Severe bleeding risk precluding anticoagulation:\n\n   1. Previous intracranial bleed unless there is documentation in the medical record (from a physician that is not part of the study) that the patient can safely use anticoagulation for 3 days\n   2. Gastrointestinal (GI) bleeding within 1 month requiring hospitalization and\u002For transfusion\n   3. Recent major surgery within 1 month if the surgical wound is judged to be associated with an increased risk of bleeding\n   4. Platelet count of less than 50,000 cells\u002Fmm3\n   5. Uncorrectable bleeding diathesis or coagulopathy\n10. Contraindicated anatomy:\n\n    1. Descending aortic anatomy that would prevent safe placement of the device (less than 18 mm or more than 28mm thoracoabdominal aorta diameter at deployment location)\n    2. Abnormalities of the aorta or subclavian or axillary arteries that would prevent safe device placement, including aneurysms, significant tortuosity, or calcifications\n    3. Axillary artery anatomy that would preclude safe placement of a 10F sheath including severe obstructive calcification or severe tortuosity\n    4. Iliofemoral artery anatomy that would preclude safe placement of a 16F introducer sheath including severe obstructive calcification or severe tortuosity\n    5. Known connective tissue disorder (e.g. Marfan Syndrome) or other aortopathy at risk of vascular injury\n    6. Prior endovascular surgery or percutaneous intervention involving the thoracoabdominal aorta or a subclavian\u002Faxillary artery or history of aortic dissection\n11. Severe aortic stenosis\n12. Known or suspected contrast induced nephropathy\n13. Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with pre-medication\n14. Absolute contraindications or allergy to unfractionated heparin (e.g., heparin-induced thrombocytopenia) or device materials (e.g. nickel, titanium) that cannot be adequately treated with pre-medication\n15. Known hematologic diseases such as leukemia, any coagulopathy or hypercoagulable state, sickle cell anemia or thalassemia\n16. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:\n\n    1. Liver disease (cirrhosis of the liver \\[Child-Pugh class B or C\\]) or shock liver\n    2. History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1\u002FFVC less than 0.7, and FEV1 less than 50% predicted\n    3. Prior kidney transplant, isolated single kidney, stage V Chronic Kidney Disease (eGFR ≤15) at admission OR use of dialysis, continuous renal replacement therapy (CRRT) or aquapheresis (ultrafiltration) in last 90 days\n17. Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation\n18. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 90 days prior to the index procedure\n19. Active infection not controlled with antibiotic therapy\n20. Suspected or known pregnancy. Women of child-bearing age should have a negative pregnancy test.\n21. Body mass index (BMI) over 40 kg\u002Fm2\n22. Unable or unwilling to undergo screening, device implant and retrieval procedures, and 30-day follow-up\n23. Currently participating in an investigational drug or another device study that may influence the data collected for this study. Observational studies are not considered an exclusion\n24. Subject has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject ability to give written informed consent and\u002For to comply with study procedures\n25. Active SARS-CoV-2 infection (Coronavirus-19 \\[COVID-19\\]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments","21 Years",{"count":509,"type":21},5,[89],"Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance",[115,27,355,513,514,515,516],"Heart Failure, Congestive","Heart Failure With Preserved Ejection Fraction","Heart Failure With Reduced Ejection Fraction","Diuretic Resistance",[518,519,520,521,522,523,524,525,526],"Puzzle Medical Devices","ModulHeart","Mechanical Circulatory Support","Intra-Aortic","MCS","LVAD","pVAD","percutaneous ventricular assist device","Left ventricular assist device","2024-06-13",{"date":492,"type":32},{"date":530,"type":21},"2024-08",{"date":532,"type":21},"2024-12",{"name":534,"class":150},"Puzzle Medical Devices Inc.",{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":17,"minAge":542,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":87,"phases":545,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":77},"100528505","mobile-education-system-to-improve-disease-knowledge-self-efficacy-and-quality-of-life-in-patients-with-heart-failure-100528505","NCT06161649","Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure","To Investigate Whether a Continuous Intelligent and Automated Mobile Education System Can Improve Knowledge, Self-care, Emotional Stress, Self-efficacy and Quality of Life in Patients With Heart Failure","Inclusion Criteria：\n\n* Patients with a diagnosis of heart failure\n* Patients with age \\>= 20 years old\n* patients with clear consciousness\n* Patients who can communicate with by Chinese or Taiwanese, and are willing to participate this study\n\nExclusion Criteria：\n\n* patients who are long-term bedridden, or living dependent of others\n* patients who have severe psychological disease, or severe cognitive dysfunction\n* patients without utilizing smartphone or internet","20 Years",{"count":544,"type":21},138,[89],"Heart failure (HF) is an incurable and complex disease syndrome with sophisticated disease trajectories. The guideline for HF management suggests that treatment should include adequate education to help patients have better self-management ability, and improve their quality of life and prognosis. However, how to provide massive amount of HF patients a continuous, complete and individualized disease care education from hospitalization, post-discharge, to home for months is a difficult problem. This study plans to develop an automated and intelligent education system for HF on the mobile device \"Line\" platform. Through this platform, we hope to make the HF education continuous for 3 months from hospital to post-discharge period. We hypothesize that (1) this intervention can improve knowledge, self-care, emotional stress, self-efficacy, quality of life and disease outcomes in patients of HF; (2) the system developed in this study can reduce the hours of nursing work while improve the quality of education and become the best clinical auxiliary education tool.",[27],[360,549,550,551,552,553,554,555],"automation","smart mobile education system","disease knowledge","self-care","emotional stress","self-efficacy","quality of life","2023-12-12",{"date":558,"type":32},"2023-12-18",{"date":560,"type":32},"2023-11-21",{"date":562,"type":21},"2026-07-31",{"name":564,"class":39},"Chang Gung Memorial Hospital",{"id":566,"slug":567,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":77},"100522329","study-of-patients-admitted-to-a-cardiac-intensive-care-unit-with-acute-cardiovascular-disease-100522329","NCT06081205","Study of Patients Admitted to a Cardiac Intensive Care Unit With Acute CardioVascular Disease","A Prospective Observational Study of Patients Admitted to a Cardiac Intensive Care Unit Due to Acute CardioVascular Disease.","Inclusion Criteria:\n\n* All patients admitted to the Cardiac Intensive Care Unit (CICU) through the Emergency Department of the UHI\n* All patients transferred to the CICU from other hospital departments or other regional secondary hospitals\n* Patients with an acute cardiovascular disease that requires treatment in a CICU\n* Patients who are under scientific supervision of the 2nd Department of Cardiology\n* Patients (or their relative\u002Flegal representatives) that have signed the informed consent form\n\nExclusion Criteria: None",{"count":573,"type":21},1000,"This is a registry of the patients that are admitted to CICU and treated by the Scientific Staff of the 2nd Department of Cardiology, due to an acute cardiovascular disease (acute coronary syndrome, acute heart failure, arrhythmia, pulmonary embolism, cardiac tamponade etc) in order to investigate the clinical characteristics of the patients, their outcome, identify the factors that could predict the in-hospital mortality and compare the results with the predicted by established risk scores. Furthermore, the study will investigate the one-year mortality and also the major adverse cardiac events (MACE - acute myocardial infarction, stroke, or cardiovascular death) will be measured.",[53,27,576,284],"Acute Pulmonary Embolism","2023-10-06",{"date":579,"type":32},"2023-10-13",{"date":581,"type":32},"2023-04-27",{"date":583,"type":21},"2027-04-26",{"name":585,"class":39},"University Hospital, Ioannina"]